Retroperitoneal fibrosis after chemotherapy.
We report the case of a patient with a non-Hodgkin lymphoma, who after a standard chemotherapy protocol, developed retroperitoneal fibrosis (RPF) in the absence of radiotherapy or other known causes. The final diagnosis was reached with the microscopic examination of tissue obtained by fine-needle aspiration and true-cut biopsy of the retroperitoneal mass. RPF can be related to chemotherapy alone.
Fassina
Ambrogio
A
Department of Pathology, Medical School, University of Padova, Padova, Italy. ambrogio.fassina@unipd.it
Boscolo Berto
Rafael
R
El Mazloum
Rafi
R
Gottardo
Fedra
F
Artibani
Walter
W
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001761:Bleomycin / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D003561:Cytarabine / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D005047:Etoposide / Q000009:adverse effects; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008727:Methotrexate / Q000009:adverse effects; D011241:Prednisone / Q000009:adverse effects; D012185:Retroperitoneal Fibrosis / Q000139:chemically induced*; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000009:adverse effects
D003561:Cytarabine; D001761:Bleomycin; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone; D008727:Methotrexate